Wednesday, September 5, 2012
Posted by D. Daniel Sokol
David W. Hull (Covington) addresses The Application of EU Competition Law in the Pharmaceutical Sector.
ABSTRACT: If the Court of Justice follows the Advocate General's advice and upholds the General Court's judgment in AstraZeneca, this may result in increased enforcement aimed at various life cycle management strategies. The Commission's current enforcement priority remains combatting practices that slow generic entry, particularly reverse-payment patent settlements. The Commission has shown a renewed interest in parallel trade, particularly dual-pricing arrangements in Spain.